A comprehensive view of Bausch & Lomb Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Sustainability & Social Responsibility Market Intelligence Service.
Emergent BioSolutions appoints Joseph C. Papa as president and CEO, succeeding interim CEO Haywood Miller from February 21, 2024; Papa previously served as CEO and Chairman at Bausch and Lomb Corporation
Published:
February 22, 2024
by Executive Appointments Monitor Worldwide
|
Bausch + Lomb introduces surgical planning software for Eyetelligence platform to streamline surgical planning and information flow; software integrates with electronic medical records and diagnostic devices, eliminating need for specific equipment
Published:
October 26, 2023
by Contify Life Science News
|
Bausch Health and its dermatology business, Ortho Dermatologics, announce FDA approval for Cabtreo Topical Gel 1.2%/0.15%/3.1%, for the topical treatment of acne vulgaris in patients twelve years of age and older
Published:
October 23, 2023
by ENP Newswire
|
Bausch + Lomb debuts Lumify Eye Illuminations in the US, a new line of hypoallergenic specialty products for the eye area; line includes 3-in-1 Micellar Cleansing Water and Eye Makeup Remover, Nourishing Lash & Brow Serum, Hydra-Gel Brightening Eye Cream
Published:
October 06, 2023
by Bausch & Lomb Inc.
|
Novartis completes divestment of front of eye ophthalmology assets to Bausch + Lomb for US$1.75B in upfront cash; assets include dry eye disease prescription drug Xiidra and SAF312 libvatrep, currently under development for chronic ocular surface pain
Published:
October 02, 2023
by ENP Newswire
|
Ask us about our Sustainability & Social Responsibility market view